-
Mashup Score: 0
The major challenges for clinicians treating older patients with acute lymphoblastic leukemia surround the emergence of resistance to existing therapies and the toxicities associated with current chemotherapies.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1
Efficacy was based on the MRD-negative CR rate at the end of induction.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet-
🎉 Breaking news! 🎉 The @US_FDA has granted accelerated approval to ponatinib with chemotherapy for adult patients with newly diagnosed Philadelphia chromosome-positive #ALL. @FDAOncology 📰 https://t.co/CHBBjBuCrF https://t.co/hNnBO8LL65
-
-
Mashup Score: 3Unique Molecular Subtypes within BCR::ABL1-Postive ALL Show Prognostic Relevance | ASH Clinical News | American Society of Hematology - 1 month(s) ago
Khylia Marshall is a freelance journalist based in Tucson, Arizona. Researchers have developed a predictive model for systematically subclassifying BCR::ABL1 -positive acute lymphoblastic leukemia (ALL) into four unique and distinct biologic and clinically relevant entities, according to a study published in Blood. There are currently two distinct diagnostic entities within BCR::ABL1 -positive ALL: lymphoid only, in which the driver gene fusion BCR::ABL1 is observed only in lymphatic precursors, and
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet-
Researchers have developed a predictive model for systematically subclassifying BCR::ABL1-positive #ALL into four unique and distinct biologic and clinically relevant entities, according to a study published in @BloodJournal. https://t.co/Xi1xBbnneq
-
-
Mashup Score: 30
The American Journal of Hematology publishes research in blood diseases in humans & animal model, covering all hematological diseases including leukemia, hemostasis and thrombosis.
Source: onlinelibrary.wiley.comCategories: General Medicine News, Hem/OncsTweet-
A new chemotherapy-free regimen of olverembatinib in combination with venetoclax and dexamethasone for newly diagnosed Ph+ acute lymphoblastic leukemia #ALL https://t.co/8eab0p1b4P https://t.co/q2f0O8vevN
-
-
Mashup Score: 1
Combining olverembatinib with blinatumomab appears to produce high complete molecular remission rates in patients with newly diagnosed, Philadelphia chromosome–positive acute lymphoblastic leukemia, says Elias Jabbour, MD.
Source: www.cancernetwork.comCategories: General Medicine News, Onc News and JournalsTweet-
Elias Jabbour, MD, discussed the use of olverembatinib as a potential new standard of care for patients with acute lymphoblastic leukemia. #ALL | @MDAndersonNews https://t.co/jYF4VjPzBv
-
-
Mashup Score: 0Treatment Advances, Challenges in ALL - 6 month(s) ago
While options for treating acute lymphoblastic leukemia (ALL) have improved in recent years, questions pertaining to treatment approaches remain, according to a session presented at the 7th Annual Live Medical Crossfire®: Hematologic Malignancies. ALL is a relatively rare malignancy, with approximately 7,000 cases diagnosed per year in the United States. It is the most common leukemia in children, but historically, adults—who comprise approximately half of the diagnoses—have been most likely to die of
Source: docwirenews.comCategories: General Medicine News, Partners & KOLsTweet-
While options for treating #ALL have improved in recent years, questions pertaining to treatment approaches remain. https://t.co/Mti3vakRBu https://t.co/LYnUKbBdB0
-
-
Mashup Score: 0What Are the Top Questions in ALL? - 6 month(s) ago
Home > What Are the Top Questions in ALL? Elias Jabbour, MD, of the University of MD Anderson Cancer Center stops by The HemOnc Pulse for a live show at the Eleventh Annual Meeting of the Society of Hematologic Oncology in Houston, Texas. In this episode, Dr. Jabbour, who is also an Associate Editor of Blood Cancers Today, the home of The HemOnc Puls e, discusses what he believes are the remaining questions in the treatment of acute lymphoblastic leukemia (ALL). He also discusses the possibility of moving
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet-
Out now🥳all-new episode of The HemOnc Pulse with our very own BCT Associate Editor Dr. Elias Jabbour. He tells @chadinabhan what he thinks are the top questions in the treatment of #ALL. Recorded 🎧live at the 11th @SocietyofHemOnc meeting. https://t.co/EI9cLkX5pN https://t.co/ljJDPo7qOu
-
-
Mashup Score: 0What Are the Top Questions in ALL? - 6 month(s) ago
Home > What Are the Top Questions in ALL? Elias Jabbour, MD, of the University of MD Anderson Cancer Center stops by The HemOnc Pulse for a live show at the Eleventh Annual Meeting of the Society of Hematologic Oncology in Houston, Texas. In this episode, Dr. Jabbour, who is also an Associate Editor of Blood Cancers Today, the home of The HemOnc Puls e, discusses what he believes are the remaining questions in the treatment of acute lymphoblastic leukemia (ALL). He also discusses the possibility of moving
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet-
Out now🥳all-new episode of The HemOnc Pulse with our very own BCT Associate Editor Dr. Elias Jabbour. He tells @chadinabhan what he thinks are the top questions in the treatment of #ALL. Recorded 🎧live at the 11th @SocietyofHemOnc meeting. https://t.co/EI9cLkX5pN https://t.co/ljJDPo7qOu
-
-
Mashup Score: 0Physicians Discuss Treatment Preference in R/R B-Cell Precursor ALL - 6 month(s) ago
During a Targeted Oncology™ Case-Based Roundtable™ event, Nicholas Short, MD, and participants discussed which patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia they would treat with inotuzumab ozogamicin.
Source: www.targetedonc.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Nicholas Short, MD, and participants discussed which patients with relapsed/refractory B-cell precursor #ALL they would treat with inotuzumab ozogamicin. #leusm | @NicholasShortMD @MDAndersonNews https://t.co/Ak3GgnRDb0
-
-
Mashup Score: 2ALL Treatment Receives FDA Approval | ASH Clinical News | American Society of Hematology - 6 month(s) ago
Blinatumomab received U.S. Food and Drug A dministration (FDA) approval for the treatment of adult and pediatric patients with CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission with measurable residual disease (MRD) greater than or equal to 0.1%. The drug previously received accelerated approval from the FDA but was granted full approval based on data from two phase III studies. The treatment is a bispecific T-cell engager immuno-oncology therapy that
Source: ashpublications.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
The #FDA approved #binatumomab, a bispecific T-cell engager immuno-oncology therapy, for treatment of adult and pediatric patients with CD19-positive B-cell precursor #ALL in first or second complete remission with MRD greater than or equal to 0.1%. https://t.co/d8dSu9hcU6
-
While most common in children, about half of #ALL cases arise in adults. Survival rates vary: over 90% for children under 15, 70-80% for adolescents/young adults, but drop for those 60+, with less than 20% survival at 3 years, & less than 10% over 75. https://t.co/d5SRAABoid